drugset / Trial / NCT04597931
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized study to determine the effects of monthly romosozumab for one year or one-time zoledronic acid on bone mineral density (BMD) and biochemical markers of bone formation and resorption, in patients with spinal cord injury (SCI) and low BMD.
Timeline
- Start
- 2020-11-01
- Primary completion
- 2023-11-15
- Completion
- 2023-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romosozumab | Monoclonal antibody | 210 mg | Subcutaneous |
| Comparator | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |